OPKO Health (NASDAQ:OPK) Stock Rating Lowered by StockNews.com

OPKO Health (NASDAQ:OPK) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Several other brokerages have also recently commented on OPK. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Stock Performance

Shares of OPK opened at $1.48 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a 50-day moving average of $1.54 and a two-hundred day moving average of $1.50. The stock has a market cap of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.62. OPKO Health has a one year low of $0.86 and a one year high of $1.76.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were bought at an average price of $1.59 per share, with a total value of $198,750.00. Following the completion of the acquisition, the chief executive officer now owns 212,536,477 shares in the company, valued at $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have acquired a total of 1,304,255 shares of company stock worth $2,024,605 in the last ninety days. 47.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OPK. American Century Companies Inc. purchased a new position in OPKO Health during the second quarter worth about $112,000. Hollencrest Capital Management lifted its holdings in OPKO Health by 14.0% in the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the period. Rubric Capital Management LP boosted its position in shares of OPKO Health by 800.0% during the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of OPKO Health in the 2nd quarter valued at about $592,000. Finally, Algert Global LLC purchased a new stake in OPKO Health during the second quarter worth about $44,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.